Skip to main content
. Author manuscript; available in PMC: 2016 Apr 19.
Published in final edited form as: Nature. 2014 Nov 27;515(7528):563–567. doi: 10.1038/nature14011

Figure 1. Programmed death-ligand 1 (PD-L1) prevalence and expression.

Figure 1

a, PD-L1 prevalence by immunohistochemistry (IHC) in samples collected for PCD4989g. PD-L1 positivity was defined as $5% of tumour-infiltrating immune cells (ICs) or tumour cells (TCs) staining for PD-L1 by IHC. b, Representative images of PD-L1 by IHC (brown) in tumours from patients with non-small cell lung cancer (NSCLC). The PD-L1-negative image is at 203 magnification, other images at 403 magnification. c, Co-localization of PD-L1 with selected tumour-infiltrating immune cell and tumour cell markers by immunofluorescence in NSCLC and melanoma tumours. PD-L1 staining in red; markers of tumour-infiltrating immune cells and tumour cells in green; and DAPI staining in blue. Areas of overlap are indicated with white arrowheads. All four images are at 403 resolution. Markers of tumour-infiltrating immune cells: CD163 (macrophages), CD11c (dendritic cells) and CD3 (T cells). Marker of tumour cells: cytokeratin (CK). CRC, colorectal cancer; HNSCC, head and neck squamous cell carcinoma; NSCLC, non-small cell lung cancer; RCC, renal cell carcinoma.